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Background: Chronic kidney disease is a common condition in the general population, 
particularly among older adults. Renal impairment is in turn associated with metabolic 
and nutritional derangements and with increased risk of cardiovascular disease.
aim: To compare the metabolic, nutritional, and cardiovascular impact of reduced kidney 
function between patients with and without known renal disease.
Materials and Methods: We enrolled consecutive outpatients (age ≥65  years) with 
reduced renal function who were divided into two groups: Group A with history of renal 
disease and Group B with unknown renal disease. Metabolic and nutritional parameters, 
including involuntary body weight loss (BWL) in the previous 6 months, mineral metabo-
lism, inflammatory indices, and left ventricular mass index (LVMI), were evaluated.
results: A total of 76 patients were enrolled. Group A (n = 39, M: 24, F: 15) showed 
greater BWL with a significant reduction of 25-hydroxyvitamin D, transferrin, cholines-
terase, albumin, and LVMI with respect to Group B (p <  0.01). Conversely, Group B 
(n = 37, M: 23, F: 14) showed significantly increased intact parathyroid hormone, total 
cholesterol, low-density lipoprotein, triglycerides, and C-reactive protein when compared 
to Group A (p < 0.05).
conclusion: The positive history of renal disease may negatively impact on several 
metabolic and nutritional parameters related to increased cardiovascular risk among 
older adults.
Keywords: older adults, chronic kidney disease, cardiovascular disease, inflammation, weight loss
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inTrODUcTiOn
Chronic kidney disease (CKD) is a common condition and it 
is increasing worldwide, particularly in adults aged ≥70  years, 
where the prevalence in the United States, Europe, and China is 
47, 35, and 28%, respectively (1, 2). The current Kidney Disease 
Outcomes Quality Initiative (KDOQI) classification system for 
CKD is mainly based on the reduction of estimated glomerular 
filtration rate (eGFR), which should be persistent for more than 
3 months, and it is classified in five stages (3). Epidemiological 
studies using this classification have highlighted that approxi-
mately 10% of the adults and 20–54% of the older adults suffer 
from CKD in stages 3–5 (4, 5). However, we do not have yet 
a nomogram of the measurement in a large sample of healthy 
individuals across the age spectrum of 20–80  years (5–7). The 
prevalence of CKD is particularly high in older adults, although 
the risk for progression to end-stage renal disease (ESRD) 
among older CKD patients is low. Therefore, the diagnosis of 
CKD should require an eGFR inappropriately low, as a conse-
quence of a known disease, and/or the presence of abnormally 
elevated proteinuria or albuminuria (8–10). In particular, Hallan 
et al. (9) suggested to consider in CKD stage 3 the presence of 
micro-, normo-, or macro-albuminuria to improve the diagnostic 
accuracy for the progression to ESRD. Several studies, including 
the Nord-Trøndelag Health Study 2 (11–13), showed that lower 
eGFR and increased albuminuria in 24-h urine collection and 
increased albumin:creatinine ratio are relevant independent risk 
factors among older adults.
The question then arises whether this lower eGFR is a conse-
quence of known kidney disease or if it is the result of aging and 
whether a stable low eGFR in older adults is sufficient or not to 
satisfy a homeostatic demand. Homeostatic failure occurs when 
eGFR is <60 ml/min/1.73 m2 and, with higher prevalence, when 
it is <45 ml/min/1.73 m2 (1, 13).
The aim of this study was to compare patients with known 
renal disease and those with eGFR <60 ml/min without known 
disease and to evaluate whether this differentially impacts 
patients’ metabolic, nutritional, and cardiovascular parameters.
MaTerials anD MeThODs
study Design and subjects
We performed an observational study on consecutive stable 
outpatients from the Nephrology Unit of Policlinico Umberto I, 
Sapienza University of Rome, Italy. The study was approved by 
the clinical research ethics committee of our University Hospital. 
The study conforms to the principles outlined in the Declaration 
of Helsinki and we obtained a written consent from each patient 
enrolled in this study. Patients with eGFR 30–60  ml/min were 
recruited in the period from January 2013 to August 2015. 
Exclusion criteria were heart failure, underlying malignancy, 
chronic liver disease, chronic obstructive pulmonary disease, 
cerebrovascular disease, acute myocardial infarction, and acute 
coronary syndrome reported in the previous 3 months. We also 
excluded patients who refused to give consent and patients with 
missing data. Patients were divided into two groups: Group A 
included patients with known renal disease and Group B those 
with eGFR <60 ml/min without known renal disease.
The Chronic Kidney Disease Epidemiology Collaboration 
equation was used to calculate eGFR (5, 14). Additionally, the 
presence of comorbidities, including diabetes and arterial 
hypertension, and current therapies were collected. Patients in 
both groups were allowed to continue their therapy with statins, 
antihypertensive, and antiplatelet drugs.
anthropometric assessment
Body weight was determined to the nearest 0.1 kg using a cali-
brated digital scale. Body mass index (BMI) was calculated by the 
formula [weight (kg)/height2 (m2)]. We also calculated the body 
weight loss in the previous 6 months.
laboratory Measurements
Blood samples were collected after an overnight fasting of at 
least 12 h. In all patients, the levels of fasting plasma glucose, 
total serum cholesterol, high-density lipoprotein (HDL), low-
density lipoprotein (LDL), triglycerides, Blood Urea Nitrogen 
(BUN), serum calcium, phosphate, sodium, potassium, serum 
uric acid, iron metabolism, including transferrin, cholinester-
ase, C-reactive protein (CRP), and erythrocyte sedimentation 
rate (ESR) were measured using standard automated techniques. 
Serum albumin was determined by bromocresol purple method. 
Parathyroid hormone was measured using a two-site assay that 
measures “intact” hormone (iPTH) (pg/mL) and 25-hydroxy-
vitamin D (25-OH Vit D) (ng/mL) by radioimmunoassay. 
LDL cholesterol was calculated using the Friedewald equation: 
LDL =  total cholesterol −  HDL −  (triglycerides/5). Arterial 
blood gas analysis was performed using a blood gas analyzer 
(Nova Phox Plus C). We have measured albuminuria in 24-h 
urine (15).
echocardiography
M-mode 2D echocardiographic examinations by a single 
experienced sonographer in the echocardiography laboratory 
and using a standard institutional protocol were completed. 
Commercially available instruments (Toshiba Aplio xV, Toshiba 
American Medical Systems, Inc., Tustin, CA, USA) equipped 
with 2.25- to 7.5-MHz imaging transducers were used. The 
subjects were in the left decubitus position, and the sonog-
rapher was blinded to all clinical details of the patients (16). 
All echocardiographic data according to the guidelines of the 
American Society of Echocardiography were recorded (17). The 
end-diastolic and end-systolic left ventricular internal diameter 
(LVED and LVES, respectively), interventricular septum thick-
ness, and posterior wall thickness were measured. The left 
ventricular mass by Devereux’s formula normalized by body 
surface area and height was estimated, and its index (LVMI) 
was also calculated (18).
statistical analysis
Data management and analysis were performed using the IBM® 
SPSS® Statistics 18 for Windows® software (IBM Corporation, 
Armonk, NY, USA). The normality of variables was tested by the 
method of Kolmogorov–Smirnov test for normal distributions. 
TaBle 2 | Patient’s nutritional, metabolic, inflammatory, and cardiac 
variables.
N patients = 76 group a (N = 39) group B (N = 37) p
Albumin (g/dL) 3.73 ± 0.51 4.69 ± 0.40 <0.0001
Cholinesterase (UI/mL) 7312 ± 2864 9647 ± 3637 0.003
Transferrin (mg/dL) 218.40 ± 37.68 266.22 ± 78.71 0.001
Hemoglobin (g/dL) 12.0 ± 0.9 14.2 ± 5.6 0.015
25-OHVitD (ng/mL) 15.36 ± 10.65 26.06 ± 12.91 <0.0001
iPTH (pg/mL) 91.4 ± 57.7 67.6 ± 29.9 0.03
Total cholesterol (mg/dL) 190 ± 32 163 ± 25 <0.001
HDL (mg/dL) 50.2 ± 11.8 44.8 ± 12.0 0.05
LDL (mg/dL) 112.0 ± 37.1 95.9 ± 21.0 0.02
Triglycerides (mg/dL) 155 ± 71 118 ± 47 0.01
Serum uric acid (mg/dL) 4.7 ± 1.1 4.3 ± 0.9 0.09
pH 7.35 ± 0.04 7.40 ± 0.03 <0.0001
Bicarbonates (mEq/L) 21.7 ± 4.1 23.0 ± 1.8 0.10
CRPa (mg/dL) 0.23 (0.13; 0.31) 0.13 (0.08; 0.29) 0.046
ESR (mm/h) 27.7 ± 16.9 16.3 ± 11.2 <0.0001
Body weight lossa (%) 3.19 (0; 5.97) 1.78 (−4.05; 1.83) 0.009
LVMI (g/m2) 141 ± 16 103 ± 20 <0.0001
Data are shown as mean ± SD.
aMedian (interquartile range) is shown for non-normally distributed variable.
25-OHVitD, 25-hydroxyvitamin D; iPTH, intact parathyroid hormone; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate; LVMI, left ventricular mass index.
Bold values indicate statistically significant p values.
TaBle 1 | Patient’s demographic and clinical characteristics.
N patients = 76 group a 
(N = 39)
group B 
(N = 37)
p
Female (N) 15 14 0.86
Age (year) 71.2 ± 4.4 72.3 ± 4.3 0.27
Body mass index (kg/m2) 23.5 ± 3.8 26.1 ± 3.5 0.003
eGFR (mL/min) 48.2 ± 10.3 52.6 ± 10.5 0.07
BUN (mg/dL) 48.13 ± 16.49 31.49 ± 8.73 <0.001
Creatinine (mg/dL) 1.7 ± 0.42 1.6 ± 0.54 0.37
Sodium (mEq/L) 139.1 ± 2.1 139.3 ± 1.8 0.66
Potassium (mEq/L) 4.1 ± 0.7 4.0 ± 0.5 0.48
Calcium (mg/dL) 9.2 ± 0.3 9.4 ± 0.6 0.07
Phosphorus (mg/dL) 4.5 ± 0.5 4.3 ± 0.4 0.06
Arterial hypertension (N) 38 15 <0.0001
Diabetes mellitus (N) 27 0 <0.0001
Chronic pyelonephritis (N) 3 0 0.26
Chronic glomerulonephritis (N) 7 0 0.02
Data are shown as mean ± SD.
eGFR, estimated glomerular filtration rate; BUN, Blood Urea Nitrogen.
Bold values indicate statistically significant p values.
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All continuous variables were expressed as mean  ±  SD, and 
categorical variables were expressed as number (percentage). 
Student’s t-test or Mann–Whitney U-test was performed to 
determine differences between groups. Binomial test or Chi-
square test was used for comparison of categorical data. Pearson’s 
or Spearman’s correlation was used to determine the relationship 
and the strength of association between the variables in bivari-
ate correlation. Potential confounders, such as age and gender, 
were included in the analyses when comparing the two groups. 
A p value < 0.05 was considered statistically significant.
resUlTs
The study included 76 consecutive patients, 29 females and 47 
males, with a mean age of 70 ± 5.4 years.
Patient’s characteristics are shown in Table 1. There were no 
significant differences between the two groups regarding sex, age, 
eGFR (mL/min), creatinine (mg/dL), sodium (mEq/L), potas-
sium (mEq/L), calcium (mg/dL), phosphorus (mg/dL), serum 
uric acid (mg/dL), HDL (mg/dL), and bicarbonates (mEq/L) 
(Tables 1 and 2).
Group A showed lower albumin (g/dL) (p <  0.0001), cho-
linesterase (UI/mL) (p = 0.003), transferrin (mg/dL) (p = 0.001), 
hemoglobin (g/dL) (p = 0.015), 25-OHVitD (ng/mL) (p < 0.001), 
and pH (p < 0.0001) with respect to Group B (Table 2). Moreover, 
Group A showed greater body weight loss (BWL) in the previ-
ous 6 months with respect to Group B (p = 0.009), higher LVMI 
g/m2 (p <  0.0001), BUN (mg/dL) (p <  0.001), iPTH (pg/mL) 
(p =  0.03), total cholesterol (mg/dL) (p =  0.02), LDL (mg/dL) 
(p  =  0.04), triglycerides (mg/dL) (p  =  0.02), CRP (mg/dL) 
(p = 0.046), and ESR (mm/h) (p = <0.0001) (Tables 1 and 2). 
The patients in Group B had reached the target blood pressure 
level by monotherapy, while those in Group A were in treatment 
with polytherapy. Proteinuria showed a different behavior in 
Group A and B. In fact, in Group A 16 out of 39 patients (41%) 
had proteinuria >1 g/24 h. In Group B, proteinuria was present in 
only 7 out of 37 patients (19%), and it was <1 g/24 h.
DiscUssiOn
The results obtained in the present study would suggest that age-
related compared to renal disease-related decline in renal func-
tion differentially impacts on patients’ metabolic and nutritional 
parameters, and possibly on cardiovascular disease (CVD) risk.
Chronic kidney disease is a common feature among older 
adults and less frequently progresses to ESRD with respect to 
younger patients (13). CVD is the most common cause of mor-
bidity and mortality associated with CKD, due to well-known 
cardiovascular risk factors in older patients and to several novel 
risk factors associated with CKD, such as abnormal nutritional 
and metabolic parameters.
In a large number of CKD patients most of these risk factors are 
present when eGFR is 60 ml/min/1.73 m2 or less (13). However, 
the relative risk associated with traditional risk factors, such as 
hypertension and hypercholesterolemia, is lower in older patients 
compared to younger ones. In older patients, there is an inverse 
relationship between traditional CVD risk factors, such as BMI, 
blood pressure, cholesterol, and all-cause mortality (19), while 
altered nutritional and metabolic derangements may represent 
negative prognostic factors in CKD.
In our study, we found that older adults with known renal 
disease have a worse nutritional and metabolic status with respect 
to patients without a known renal disease. This is reflected by the 
presence of alteration of metabolic and inflammatory profile and 
by altered cardiovascular index (LVMI), although the eGFR was 
comparable between the two groups.
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Only patients in Group B achieved the lipid target range 
recommended by the European and Canadian guidelines (20), 
although the recent American guidelines give more importance 
to the modification of lifestyles, instead of targeting strict lipid 
levels (21). Considering the high prevalence of diabetes among 
patients in Group A, the cholesterol levels were above the rec-
ommended range, representing a further relevant risk factor 
for cardiovascular events. Also, triglycerides were significantly 
higher in Group A with respect to Group B (>150 mg/dl) (20).
The KDOQI classification considers the eGFR of 50  ml/
min/1.73 m2 as indicative of moderate CKD (stage 3), independ-
ent of age. It has been recognized that the physiological aging 
process of the kidney leads to a loss of GFR at a rate of about 
1 ml/min/1.73 m2 per year after 40 years of age (22, 23). Two large 
studies found that moderate reductions in eGFR were not associ-
ated with increased mortality among older adults (i.e., ≥60 years 
of age in one study and ≥65 years in the other study) (24, 25). In 
contrast, in a meta-analysis performed by the Chronic Kidney 
Disease Prognosis Consortium (26), an association was present 
between eGFR <60 ml/min/1.73 m2 and increased all-cause and 
cardiovascular mortality among adults ≤65 years of age and their 
counterparts ≥65 years of age (27).
Conversely, in a large cohort of veterans who fulfilled criteria 
for CKD stage 3 or higher, the prognostic implications of eGFR 
for death and ESRD varied greatly depending on the age (28). 
Moreover, Davies and Shock (29) showed that mean GFR (meas-
ured using the gold standard of inulin clearance) decreased from 
123 ml/min/1.73 m2 at age 20–29 years to 65 ml/min/1.73 m2 at 
age 80–89 years.
Cross-sectional evaluations of measured GFR and eGFR 
in healthy individuals, e.g., potential kidney donors, showed a 
reduction in the mean value of 6–8 ml/min/1.73 m2 per decade 
(30). This indicates that there is a real reduction in renal func-
tion among older adults. Available data showed that, at least 
until the age of 80  years, the renal functional reserve, i.e., the 
increase in eGFR after an amino acid load, was preserved in these 
subjects independent of gender (31, 32). Hollenberg et  al. (33) 
demonstrated a reduction of the renal vasodilatory response to 
acetylcholine in older kidney donors. Furthermore, the arterial 
wall is substantially remodeled with aging even in the healthy 
subjects. Histological changes such as glomerulosclerosis, tubular 
atrophy, interstitial fibrosis, and arteriolar sclerosis, which are 
typical findings of the common pathway of progressive CKD, are 
increasingly found with aging even in the absence of hyperten-
sion and diabetes or other chronic diseases (4, 12). Data from 
the PREVEND study have shown that eGFR were independently 
and significantly associated with cardiovascular events only 
in subjects <60 years of age (34). Indeed, a stable low eGFR in 
older adults, provided that it is physiologically sufficient to meet 
homeostatic demands, cannot be considered as a disease per se 
and rarely progresses to kidney failure, even if it implies a reduced 
reserve and vulnerability to drugs overdosing and increased risk 
of acute kidney injury (AKI) (13).
The complications related to reduced eGFR would be abnor-
mal sodium balance causing hypertension, a blunted erythropoi-
etin axis causing anemia, and disturbed calcium and phosphate 
balance causing secondary hyperparathyroidism and metabolic 
acidosis (11).
In our study, the homeostatic and metabolic disorders were 
significantly increased in patients with positive history of renal 
disease (Group A), although also patients with no history for 
disease (Group B) showed depletion of vitamin D. In particular, 
Group A showed a more pronounced depletion of vitamin D with 
respect to Group B, being associated with a small but significant 
increase of iPTH. Moreover, Group A showed a worsening trend 
of nutritional status, with a significant reduction in albumin and 
cholinesterase levels, lower BMI, and greater BWL in the previ-
ous 6 months. In Group A, we also found a significant reduction 
in hemoglobin levels, although these values were within the 
therapeutic range for patients with eGFR ≤60 ml/min (35), and 
they were associated with mild iron deficiency and increased 
inflammatory status. We observed significant increase of LVMI 
in Group A, which might be influenced by several factors, includ-
ing hyperparathyroidism, and by the higher rate of hypertension 
documented within this group. Based on these observations, 
patients with history of renal disease may require a more careful 
follow-up visit, with assessment of nutritional and metabolic 
status compared with those with similar eGFR but with unknown 
underlying renal disease. These findings question the clinical 
relevance of a standard stage-based approach to the management 
of CKD, which is supported in most of the available international 
guidelines and focus on the critical need to use stronger prog-
nostic tools for an early identification of older adults who will 
progress from CKD to ESRD, CVD, or AKI (36). Moreover, the 
current staging system for CKD is largely based on the concept 
that GFR ≥90 ml/min/1.73 m2 is normal, 60–89 ml/min/1.73 m2 
is reduced, and ≤60 ml/min/1.73 m2 is always abnormal, inde-
pendent of the presence of kidney damage (37, 38). This approach 
does not take into account the biological variability and the renal 
reserve (39, 40).
The average eGFR is variably decreased in older adults, as a 
consequence of biological aging and underlying comorbidities 
(41). In some patients, the decline of renal function is enhanced 
by concomitant CVDs, and a low eGFR may be the consequence 
of aging and concomitant underlying diseases (42, 43).
As supported by other evidences, in older patients with CKD 
we should consider not only the eGFR and the presence of pro-
teinuria but also the underlying renal disease (44, 45). Moreover, 
we should assess in this population the nutritional and metabolic 
status in order to better stratify cardiovascular risk and to imple-
ment tailored therapeutic interventions (46, 47).
We acknowledge the limitations of our study. The small 
sample size might have limited the possibility to recognize asso-
ciations between patients’ clinical characteristics. In this light, 
the present cohort of patients may not be representative of the 
entire CKD outpatient population. In particular, we included a 
large proportion of patients on antiplatelet and antihypertensive 
therapies and on statins and the potential impact of hypertension, 
hypercholesterolemia, and their treatments on LVMI may have 
potentially confounded our results. Although both groups were 
affected by hypertension, Group A had a higher prevalence of 
this condition probably determining the significant difference 
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observed in LVMI. Approximately 40% of patients in Group B 
suffered hypertension. This may be associated with the reduction 
of eGFR. However, in contrast with Group A, patients in Group B 
were treated with antihypertensive monotherapy, showing blood 
pressure values within normal range.
cOnclUsiOn
In spite of comparable eGFR, older adults with underlying renal 
disease have a worse nutritional and metabolic balance with 
respect to patients with negative history. This is reflected by the 
presence of alterations of metabolic and inflammatory profile and 
by impaired cardiovascular index.
Integrated care for older adults with loss of renal function 
should go beyond a focus on reduced eGFR or proteinuria and 
include consideration of underlying cause of kidney disease.
Based on our results, it might be helpful to prospectively 
evaluate the impact of nutritional alterations on clinical 
outcomes and health-care costs in older adults with impaired 
renal function.
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